Amgen Inc. Stock price

Equities

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX 15:14:11 2024-02-23 EST 5-day change 1st Jan Change
289 USD +1.35% Intraday chart for Amgen Inc. +2.05% +0.52%
Sales 2024 * 32.87B 44.35B Sales 2025 * 34B 45.89B Capitalization 153B 206B
Net income 2024 * 6.19B 8.35B Net income 2025 * 7.43B 10.02B EV / Sales 2024 * 6.09 x
Net Debt 2024 * 47.48B 64.08B Net Debt 2025 * 42.05B 56.74B EV / Sales 2025 * 5.73 x
P/E ratio 2024 *
24.6 x
P/E ratio 2025 *
19 x
Employees 26,700
Yield 2024 *
3.24%
Yield 2025 *
3.51%
Free-Float 99.63%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.63%
1 week+2.43%
Current month-7.53%
1 month-6.23%
3 months+9.47%
6 months+12.91%
Current year+0.89%
More quotes
1 week
280.55
Extreme 280.55
292.24
1 month
280.55
Extreme 280.55
329.72
Current year
280.55
Extreme 280.55
329.72
1 year
211.71
Extreme 211.71
329.72
3 years
198.64
Extreme 198.64
329.72
5 years
166.30
Extreme 166.3
329.72
10 years
108.20
Extreme 108.2
329.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 06-05-31
Director of Finance/CFO 65 19-10-22
Chief Tech/Sci/R&D Officer 61 04-12-31
Members of the board TitleAgeSince
Director/Board Member 67 17-02-02
Director/Board Member 68 16-10-13
Director/Board Member 75 14-10-16
More insiders
Date Price Change Volume
24-02-23 289.5 +1.51% 1 504 837
24-02-22 285.2 +0.61% 2,992,891
24-02-21 283.5 -0.02% 1,934,490
24-02-20 283.5 -0.07% 3,402,126
24-02-16 283.7 -1.86% 3,596,798

Delayed Quote Nasdaq, February 23, 2024 at 12:50 pm

More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.6% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
285.2 USD
Average target price
303.6 USD
Spread / Average Target
+6.48%
Consensus
1st Jan change Capi.
+0.89% 153 B $
+31.33% 693 B $
+21.62% 552 B $
+3.13% 386 B $
+18.59% 328 B $
+14.56% 312 B $
+7.97% 210 B $
-4.95% 209 B $
-3.58% 197 B $
-2.99% 156 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Amgen Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer